TY  - GEN
AU  - Thomas,M
AU  - Ponce-Aix,S
AU  - Navarro,A
AU  - Riera-Knorrenschild,J
AU  - Schmidt,M
AU  - Wiegert,E
AU  - Kapp,K
AU  - Wittig,B
AU  - Mauri,C
AU  - Dómine Gómez,M
AU  - Kollmeier,J
AU  - Sadjadian,P
AU  - Fröhling,K-P
AU  - Huber,R M
AU  - Wolf,M
TI  - Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study
SN  - 1569-8041
PY  - 2019///1125
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Carboplatin
KW  - administration & dosage
KW  - Cisplatin
KW  - Cohort Studies
KW  - Etoposide
KW  - Follow-Up Studies
KW  - Humans
KW  - Immunosuppressive Agents
KW  - Immunotherapy
KW  - International Agencies
KW  - Leflunomide
KW  - Lung Neoplasms
KW  - drug therapy
KW  - Maintenance Chemotherapy
KW  - Prognosis
KW  - Small Cell Lung Carcinoma
KW  - Survival Rate
KW  - Toll-Like Receptor 9
KW  - agonists
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1093/annonc/mdy326
ER  -